

August 7, 2018

Letter from AntiCancer's Founder, Robert M. Hoffman

Dear Friends, Colleagues, Customers, and Followers:

Greetings and heartfelt thank you to the many thousands of you who have supported AntiCancer, Inc.'s scientific and product developments over the past 35 years.

We continue with our great scientific endeavors to discover and develop a better means to improve individualized cancer therapy for all patients. AntiCancer's patient-derived orthotopic xenograft PDOX[®] mouse models, developed over the past 30 years, continues to be further developed to greater levels. The PDOX[®] model uses surgical orthotopic implantation, a technique AntiCancer patented in 1996.

The AntiCancer PDOX[®] team has been responsible for all the major developments in the PDOX[®] models over the past 30 years. The current team comprises eight superbly-skilled microsurgeon/scientists. This team includes:

1. Takashi Higuchi, MD
2. Yuki Katsuya, MD
3. Kentaro Miyake, MD, PhD
4. Hiromichi Oshiro, MD
5. Jun Ho Park, M.D.
6. Sahar Razmjooei, MD
7. Norihiko Sugisawa, MD
8. Janice Zhang, MD

More than 100 scientific papers have been published on the PDOX[®] models by the AntiCancer PDOX[®] teams since 1991, and more than 500 papers have been published by AntiCancer on all its animal models of cancer.

The AntiCancer PDOX[®] team can meet all your needs and conditions for individualized therapy, drug discovery, and drug evaluation research. The PDOX[®] model most closely represents the clinical cancer patient and its results are clinically relevant.

We are happy to report a very new development, which is described in the News Release found on this website issued August 6, 2018, demonstrating our latest discovery to increase the establishment rate of patient tumors in nude mice to extremely high levels, thereby opening the possibility of PDOX[®] models for all cancer patients ([put link here](#)).

Please let us know how we can serve your needs using AntiCancer's PDOX[®] models. We have satisfied thousands of customers and patients over these past 35 years and will continue even more so as we move forward.

With best wishes,

Robert M. Hoffman, Ph.D.
Founder, President, and CEO
AntiCancer, Inc.
Professor of Surgery, UCSD
Em: all@anticancer.com